Subgroup analysis of Japanese patients in a phase III randomized, controlled study of neoadjuvant atezolizumab or placebo, combined with nab-paclitaxel and anthracycline-based chemotherapy in early triple-negative breast cancer (IMpassion031).

In conclusion, in Japanese patients with early stage TNBC, the numerical improvement in pCR observed with atezolizumab combined with neoadjuvant nab -paclitaxel, followed by doxorubicin and cyclophosphamide, versus that with placebo showed a trend directionally consistent with that observed in the global IMpassion031 study population.

also in 53,322 other papers